Merck faces falling sales for other key drugs including a blockbuster HPV vaccine and diabetes medication.

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...

Merck KGaA (Merck) has dosed the first patient in its Phase III clinical programme, ELOWEN-1 and ELOWEN-2, evaluating the ...

Shares of Merck & Co. , Inc. (NYSE:MRK) climbed more than 4% in premarket trading on Thursday after the company reported ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ...

The multi-year partnership, valued at up to $1 billion, will integrate Google's Gemini Enterprise AI across Merck's core ...

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...